# Alector Inc. (ALEC) fundamentals

Data as of 2026-11-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.29, market value $341 million.

## Valuation
- **P/E (trailing): 6.2×**. Alector Inc. trades at 6.2× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 2.0×**. Each dollar of revenue is priced at 2.0×.
- **Price / book: 2.2×**. The shares trade at 2.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 7.3×**. Enterprise value is 7.3× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: -44.0%** (5-yr avg -50.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 16.2%**. The inverse of the P/E: 16.2% of the price is earned each year.

## Profitability
- **Operating margin: 20.2%**. 20.2% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -679.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -466.3%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -108.5%**. Return on all capital, debt included, is -108.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 14.1%**. Each dollar of assets produces 14.1% of profit.

## Growth
- **Revenue growth (1 yr): -79.1%** (3-yr -46.0%/yr, 5-yr -0.1%/yr). Revenue fell 79.1% over the last year, against -0.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -13.0%**. Earnings per share fell 13.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.32**. Debt is 0.32 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Alector Inc. holds more cash than debt.
- **Current ratio: 3.83** (quick 3.83). Current assets cover the next year's liabilities 3.83 times.
- **Altman Z-score: 0.05**. A Z-score of 0.05 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Alector Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (5 analysts). 5 analysts cover Alector Inc.; the consensus is hold, with an average price target of $3.90 (+70% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 76.2%** (YTD 46.8%, 3-mo 28.7%). The shares are up 76.2% over twelve months including dividends.
- **From 52-week high: -17.0%** (110.1% above the low). Trading 17% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.80** (volatility 84%). Beta of 1.80 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALEC · Page: https://foliofundamentals.com/stocks/alec

Not investment advice.